Background Cardiovascular disorders associated with endothelial dysfunction, such as
atherosclerosis, have decreased nitric oxide (NO) bioavailability. Arginase in the vasculature …

Arginase can cause vascular dysfunction by competing with nitric oxide synthase for l-
arginine and by increasing cell proliferation and collagen formation, which promote vascular …

Arginase may play a major role in the regulation of vascular function in various
cardiovascular disorders by impairing nitric oxide (NO) production. In the current study, we …

Decreased endothelial nitric oxide (NO) bioavailability as it relates to endothelial dysfunction
plays an important role in various cardiovascular disorders, including atherosclerosis …

Oxidized low-density lipoproteins increase arginase activity and reciprocally decrease
endothelial NO in human aortic endothelial cells. Here, we demonstrate that vascular …

Arginase, expressed in endothelial cells and upregulated in aging blood vessels, competes
with NO synthase (NOS) for l-arginine, thus modulating vasoreactivity and attenuating NO …

Arginase upregulation is associated with aging and cardiovascular diseases. In this study
we report on the cardiovascular phenotype of the arginase II knockout (KO) mouse. We …

The incidence of cardiovascular disease is predicted to increase as the population ages.
There is accumulating evidence that arginase upregulation is associated with impaired …

Enhanced vascular arginase activity can impair endothelium-dependent vasorelaxation by
decreasing l-arginine availability to endothelial nitric oxide (NO) synthase, thereby reducing …

Enhanced vascular arginase activity impairs endothelium-dependent vasorelaxation by
decreasing l-arginine availability to endothelial nitric oxide (NO) synthase, thereby reducing …